UroToday.com shared a post on X:
“NIAGARA trial shows durvalumab + chemotherapy improves survival in MIBC.
Tom Powles, Barts Cancer Institute (Queen Mary) and Zach Klaassen discuss the NIAGARA trial results which examined the addition of durvalumab to cisplatin-based chemotherapy in the perioperative setting for muscle-invasive bladder cancer, representing the largest trial in this space with 1,000 patients.
Full Video on UroToday.